That certainly won't derail the oncology division however. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. The surge in revenues can primarily be attributed to its Allergan. My No. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. The material provided on this website is for information purposes only and should not be understood as an investment advice. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. As such I have downgraded my own growth expectations in the forecasting table above, reducing annual growth from 7.5%, to just 2.5%, after forecasting for $5bn revenues in FY22 - down 7.5% year-on-year. Please log in to your account or sign up in order to add this asset to your watchlist. Your current $100 investment may be up to $188.28 in 2028. It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. Receive regular, detailed analysis focused on biotech and healthcare stocks. All Rights Reserved. That reflects uncertainty about what the future holds for AbbVie. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. What is ABBV's Earnings Per Share (EPS) forecast for 2023-2025? Real-time analyst ratings, insider transactions, earnings data, and more. Please. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. The major market events for the week ahead right in your inbox. On average, analysts rate AbbVie stock as a buy. ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. Always conduct your own due diligence before investing. I believe AbbVie is likely 15 - 20% undervalued at current price. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. The company didn't offer a . With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. You should do your own research and never invest money you cannot afford to lose. As we can see, AbbVie is likely to generate some impressive cash flow based on its operating margins, which begin at 32%. AbbVie has been working hard to ensure the 2 drugs it has developed to replace Humira - Skyrizi, which inhibits the pro-inflammatory cytokine IL23, and Rinvoq, a Janus Kinase (enzymes involved in immune cell function) inhibitor - are winning approvals and growing sales in Humira's markets. AbbVie discounted cash flow analysis. Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. AbbVie Inc. is a US-based biopharma company with global operations. AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. AbbVie says it will pay down debt of $4bn in 2023, which will "bring cumulative debt pay down ~$34bn", but the company is heavily reliant on maintaining an investment grade rating. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. All rights reserved. I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. Payout ratios above 75% are not desirable because they may not be sustainable. AbbVie product revenues by quarter and year since FY20. In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. on the strength of its future rather than present portfolio. The difference between trading assets and CFDs. AbbVie's stock was trading at $161.61 on January 1st, 2023. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. AbbVie CEO Gonzalez told the audience at the JPM Healthcare conference that: We now have a little over 90% access for next year for Humira at parity. View institutional ownership trends. That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain. Please disable your ad-blocker and refresh. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I am not receiving compensation for it (other than from Seeking Alpha). View AbbVie's Short Interest. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. ABBV currently yields 4.1% and has raised its dividend every year since 2013. (ABBV) AbbVie Stock Predictions from the Leading Provider of Short and Long Term Stock Price Forecasts. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. AbbVie (NYSE:ABBV) has a market capitalization of $276.13 billion and generates $58.05 billion in revenue each year. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. The five-year dividend growth rate is just below 18%. Trial results demonstrated an overall response rate of 63% and a median duration of response of 12 months, where 39% of patients had already tried a CAR-T cell therapy. Trading CFDs is high risk and is not suitable for everyone. I suspect Eye Care is a division AbbVie can turn around given time, and I feel that with regards to oncology, where AbbVie has the strongest pipeline assets - lymphoma bispecific Epcoritamab may be approved to treat large B-cell lymphoma, and peak sales estimates range from $1.5 - $3bn, although AbbVie will not earn all of that since the product is co-developed with Genmab. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. You should never invest money you cannot afford to lose. The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. ABBV has several positive factors pushing its price performance. During the same quarter in the prior year, the firm posted $3.31 EPS. Date. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. This indicates that AbbVie will be able to sustain or increase its dividend. The most recent increase was . As we can see above one of either Skyrizi or Rinvoq has now been approved for all of the same indications as Humira is, except for Hidradenitis Suppurativa, although Rinvoq is undergoing a Phase study in this indication. The dividend payout ratio of AbbVie is 89.56%. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. I write about Biotech, Pharma and Healthcare stocks and share investment tips. And it couldnt be more wrong! Skyrizi has shown superiority to Humira in fields such as plaque psoriasis by a statistically significant amount, with a comparable safety profile, whilst Rinvoq has shown superiority in e.g. PEG Ratios above 1 indicate that a company could be overvalued. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. AbbVie projected sales - immunology (my forecasts and assumptions). What that means is, essentially it will be on formulary with biosimilars, but there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. AbbVie could be the biggest global Pharma by revenue generation in 2028. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. We now expect global sales for Skyrizi to reach more than $10 billion in 2025, an increase of $2.5 billion versus our previous guidance, reflecting higher performance across basically all of the indications. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. Forecast . The total revenue in 2021 was $56.20 billion with a 31% operating margin. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. The average price target represents a 6.33% change from the last price of $153.90. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. Investors are already flocking there for a chance at 1,000%+ returns. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. In the next year, analysts predict that Revenue will reach C$253.83M - an increase of 3.50%. AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX). Abbvies first quarter 2022 financial results for the quarter ended 31 March revealed that diluted earnings per share (EPS) increased to $2.51 on a generally accepted accounting principles (GAAP) basis, up from $1.99 a year earlier. As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Rinvoq's progress has been a little more circumspect, but almost as impressive. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. AbbVie's stock is owned by many different institutional and retail investors. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. On average, they expect the company's stock price to reach $161.12 in the next twelve months. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. This year is off to a strong start. (AbbVie JPM Healthcare conference presentation). When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. AbbVie has been increasing its dividend for 51 years. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. Without the additional patents - >130 in total - Humira would have lost its market exclusivity in 2016, but having eventually lost protection in Europe, which has resulted in a sales decline from $6.3bn in 2018, to ~$2.7bn in 2022, Humira will finally face generic competition in the US from the beginning of this year. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. I am not receiving compensation for it (other than from Seeking Alpha). (my tables and forecasting). In the past I have written about the high level of competition between major Pharma in the auto-immune space - for example, for Psoriatic Arthritis the list of approved drugs includes Humira, UCB Pharma's Cimzia, Amgen's Enbrel, Johnson & Johnson's (JNJ) Stelara, Eli Lilly's (LLY) Talzt, Novartis' (NVS) Cosentyx and Bristol-Myers Squibb's (BMY) Orencia. Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". (844) 978-6257. Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. Join the 500.000+ traders worldwide that chose to trade with Capital.com, Also you can contact us: Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. In summary, the total revenue increase of just 4% year-on-year in Q2'22 might disappoint a few investors, as might the downgraded guidance, although it is hard to argue that AbbVie is a bad investment when we consider that the Pharma also pays a dividend of $1.41 per quarter, yielding 4% per annum, drove operating earnings of $3.925bn on a GAAP basis, and trades at a >10% discount to my calculated target price. I wrote this article myself, and it expresses my own opinions. Management puts this down to "delayed market recovery for new patients starting therapy in Chronic Lymphocytic Leukemia ("CLL") and increasing competition" and has downgraded its FY22 guidance as a result. AbbVie Oncology Division Forward Revenue Projections (my table and assumtpions). What guidance has AbbVie issued on next quarter's earnings? By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. Since then, however, the stock price has fallen 18% to its current price of $142.6. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Outside of Humira, management does not have to worry about LOEs for any of its other portfolio products before the end of the decade, which is encouraging, however, based on my own projections of how AbbVie will generate its revenues between 2023 and 2030, if management wants to drive a CAGR in the high single digits after 2025, it will need some help from its pipeline - not an area of particular strength for AbbVie. Receive regular, detailed analysis focused on biotech and healthcare stocks. I'm on twitter @edmundingham. Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally. Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. RHHBY vs. ABBV: Which Stock Is the Better Value Option? Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. Furthermore, it seems sales of Lupron and Synthroid have joined the "All Other" section, which has generated $2.2bn of revenues in the first half of 2022, versus $1.5bn in the first half of 2021. If you have an ad-blocker enabled you may be blocked from proceeding. Please. The AbbVie of today has 5 thriving divisions - Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care - with the latter 3 divisions acquired from Allergan as part of AbbVie's $63bn takeover of that company.